A new study suggests that high doses of vitamin D supplements could help reduce disease activity among multiple sclerosis ...

Treatment with high-dose vitamin D reduced disease activity in people with clinically isolated syndrome in a Phase 3 trial.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III MUSETTE trial comparing a high dose of OCREVUS® (ocrelizumab) intravenous (IV) infusion to the currently approved OCREVUS IV 600 ...

At one point during her health journey, Chandler resident Erin Kienlen thought she had amyotrophic lateral sclerosis, or ALS.

NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...

Alberto Ascherio and Stephen Hauser were recognized for their work uncovering the role of B cells and Epstein Barr virus in ...

MS patients may receive less frequent rituximab infusions without increasing their chances of relapse or disease progression, ...

Roche’s phase III MUSETTE trial of Ocrevus high dose in people with relapsing multiple sclerosis fails to meet primary endpoint: Basel Friday, April 4, 2025, 11:00 Hrs [IST] Roc ...